Kezar Life Sciences appoints Courtney Wallace to board; director Jason Dinges resigns

Kezar Life Sciences, Inc.

Jason Dinges, Ph.D., resigned from the board effective Dec 9, 2021; departure not due to disagreement.
Courtney Wallace appointed as Class I director, serving until 2022 annual meeting or successor.
Wallace receives annual cash compensation of $35,000 plus initial option for 52,000 shares vesting monthly over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason Dinges

Director

KZR · Kezar Life Sciences, Inc.

Effective: 2021-12-09
Filed: December 10, 2021, 6:59 PM ET

Effective December 9, 2021, Jason Dinges, Ph.D., resigned from the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) and from his position as a member of the Nominating and Corporate Governance Committee of the Board.

Appointed

Courtney Wallace

Director

KZR · Kezar Life Sciences, Inc.

Effective: 2021-12-09
Filed: December 10, 2021, 6:59 PM ET

Effective December 9, 2021, the Board appointed Courtney Wallace to the Board as a Class I Director, to serve until the Company’s 2022 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Dinges resigned as Director at Kezar Life Sciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective December 9, 2021, Jason Dinges, Ph.D., resigned from the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) and from his position as a member of the Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Courtney Wallace was appointed as Director at Kezar Life Sciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective December 9, 2021, the Board appointed Courtney Wallace to the Board as a Class I Director, to serve until the Company’s 2022 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier resignation or removal.

View on SEC.gov

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-060020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.